Molecular Insight is a privately held, emerging biopharmaceutical company based in Cambridge, Massachusetts. The company is focused on leveraging its proprietary technology platforms to develop innovative imaging pharmaceuticals that improve the visualization and management of disease. Molecular Insight has established a strong pipeline of product candidates focused on the large markets in cardiology, infectious disease, cancer and neurology. The company's lead compound, BMIPP for the detection of ischemia, is nearing completion of multi-center Phase II clinical trials.

The company's technology platforms are producing new radiopharmaceuticals that have the potential to detect the earliest changes in the molecular biology of the cell. Specific changes in gene expression, protein expression, protein function and biochemistry provide important insights into the nature and status of disease. These new technologies also promise to offer safer, more effective and less costly imaging procedures.

Molecular Insight's management team is led by David S. Barlow, Chairman and CEO. He has more than 20 years of management experience and achievements in the biopharmaceutical industry, most recently as President of Sepracor Pharmaceuticals. John W. Babich, Ph.D., President and CSO is a leader in the field of medical imaging and nuclear medicine and formerly on the faculty of Harvard Medical School and Massachusetts General Hospital. John E. McCray, Chief Operating Officer, has more than 20 years of operations, public policy experience in the biopharmaceutical industry. The company's scientific advisory board is chaired by William C. Eckelman, Ph.D., Chief of Positron Emission Tomography at the NIH Clinical Center.

Last Updated: 02-02-2007